Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Morgan Stanley upgraded Merck (MRK) to overweight, raising its price target to $179 from $116, citing a strong cancer drug pipeline. The bank believes Merck's pipeline, including drugs for oncology and inflammatory bowel disease, will offset the 2028 patent expiration of Keytruda. Merck shares have risen 45% year-to-date, with Keytruda generating over $16 billion in sales in the first half of 2023.
How this was made
The 30-second read
Why it matters
Analyst upgrade suggests near-term upside; long-term risk remains around patent cliff.
Market read
Upgrade may drive Merck stock higher, influencing pharma sector sentiment.
What to watch
Potential competition from emerging immunotherapies not fully accounted for.
Background
Merck's Keytruda sales remain strong, but patent expiration looms in 2028; analyst sees pipeline as offset.
Ticker impact
Morgan Stanley upgraded Merck to overweight and raised price target to $179, citing pipeline growth despite Keytruda patent expiry.
Short-term price rally expected as investors reprice target.
Analyst upgrade with a concrete price target on a large-cap pharma is a strong catalyst.
Market effects
May lift broader pharma sector as pipeline optimism spreads.
U.S. market likely sees modest gain; European peers may see similar sentiment.
Limited to pharma and biotech investors worldwide.
Counterpoint
Keytruda patent expiry could still pressure margins if pipeline delays occur.
Key entities
- CompanyMerck & Co.
Pharmaceutical giant with flagship drug Keytruda.
- AnalystMorgan Stanley
Investment bank providing upgrade and price target.
